A first-generation acylated GLP-1 analog. A palmitic acid chain confers albumin binding and a roughly 13-hour half-life, permitting daily dosing. Mechanism otherwise parallels semaglutide: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central appetite reduction.
LEAD programme in type 2 diabetes; SCALE programme in weight management; LEADER reported cardiovascular outcomes. A mature evidence base, now largely superseded in potency by later agents.
FDA-approved for type 2 diabetes and chronic weight management. Prescription-only. Generic versions have entered the market.
Boxed warning for rodent thyroid C-cell tumours. Gastrointestinal effects; pancreatitis and gallbladder signals. Physician supervision required.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.